Brief: Cytrx completes enrollment in lung cancer mid-stage study

LadRx

07/09/2016 14:01

Sept 7 (Reuters) - Cytrx Corp  CYTR.O  
    * Says Completion Of Enrollment In Its Global Phase 2b 
Clinical Trial Of Aldoxorubicin In Patients With Second Line 
small cell lung cancer 
    * If global phase 2b clinical trial results are positive, co 
intends to meet with u.s. FDA or submission of NDA for 
aldoxorubicin 
 
Source text for Eikon:  ID:nPnLTLqZa  
Further company coverage:  CYTR.O  
 
 ((Bangalore.newsroom@thomsonreuters.com ;))